Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
The latest news, research, and perspectives in myeloproliferative neoplasms (MPNs). MPNs occur when the bone marrow produces too many red blood cells, platelets, or certain white blood cells. The primary subtypes include myelofibrosis, polycythemia vera, and essential thrombocythemia.
Advertisement
Melissa BadamoPolycythemia Vera | May 24, 2025
Interferon improved myelofibrosis-free survival in adolescent and young adult patients with polycythemia vera.
Rahul Banerjee, MD, FACPAcute Myeloid Leukemia | May 23, 2025
Experts discuss early detection in myeloid malignancies, from current challenges to future innovations.
Melissa BadamoAcute Lymphoblastic Leukemia | May 16, 2025
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Andrew MorenoPolycythemia Vera | May 13, 2025
This agent also has Orphan Drug designation from the EMA and a phase III study is currently enrolling patients.
Pankit Vachhani, MDMyelofibrosis | May 12, 2025
Experts discuss patient-centered approaches and novel therapies reshaping MF treatment in a roundtable.
Prithviraj Bose, MDMyelofibrosis | May 12, 2025
Experts explore anemia therapies, JAK inhibitors, and transplant innovations shaping the promising future of MF care.
Advertisement
Naseema Gangat, MBBSMyelofibrosis | May 12, 2025
Experts discuss molecular insights into MF, highlighting mutations, risk assessment, and evolving therapeutic approaches.
Prithviraj Bose, MDMyelofibrosis | May 12, 2025
Experts discuss current treatments and ongoing research in myelofibrosis, highlighting new therapies and clinical trials.
Idoroenyi Amanam, MDMyelofibrosis | May 12, 2025
Experts discuss CALR-targeting therapies, symptom assessment, and the future of myelofibrosis treatment and regulation.
Melissa BadamoAcute Lymphoblastic Leukemia | May 8, 2025
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
Andrew MorenoTransplantation & Cellular Therapy | April 25, 2025
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
Melissa BadamoAcute Lymphoblastic Leukemia | April 23, 2025
The Community Oncology Alliance outlined solutions for Congress to address systemic challenges of the U.S. healthcare system.
Melissa BadamoAcute Lymphoblastic Leukemia | April 8, 2025
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
Andrew MorenoMyelofibrosis | March 28, 2025
Investigators observed that overall treatment has improved but hospitalizations and other events indicate unaddressed need.
Melissa BadamoMyelofibrosis | March 27, 2025
Harboring high molecular risk mutations and a lower JAK2V617F VAF were independent adverse prognostic factors for survival.
Andrew MorenoMyelofibrosis | March 27, 2025
The Myelofibrosis Symptom Assessment Form is the only instrument currently available for evaluating myelofibrosis symptoms.
Nichole TuckerMyelofibrosis | March 25, 2025
According to John O. Mascarenhas, MD, the phase 3 MANIFEST study heralds a new era of combination therapy for myelofibrosis.
Andrew MorenoPolycythemia Vera | March 25, 2025
In a phase 2 trial the hepcidin mimetic increased hematocrit control while reducing phlebotomy and patient-reported symptoms.
Melissa BadamoMyelofibrosis | March 25, 2025
Most patients with JAK2, CALR, and MPL mutations had mutation clearance 100 days after HSCT.
Andrew MorenoPolycythemia Vera | March 19, 2025
A study found limits to the prediction utility of thrombosis history in patients with PV and pulmonary hypertension risk.
Advertisement
Advertisement